AI Takeaway
Merck (MRK) delivered modest revenue growth of 1.3% to $65.0B in FY2025, with net income rising 6.6% to $18.3B and EPS up 8.0% to $7.28, though operating cash flow declined 23.3% and long-term debt surged 35.7% amid significant investing activity.
Revenue
$65.01B
++1.31% YoY
EPS (Basic)
$7.30
++7.99% YoY
Filed · Analysis updated · Source: SEC EDGAR 10-K filing
Total revenue grew 1.3% year-over-year to $65.0B in FY2025, reflecting continued demand for Merck's key pharmaceutical products despite competitive pressures and potential patent cliff concerns. The modest top-line growth suggests the company is maintaining its market position while navigating a complex product mix.
Source: Source: 10-K Income Statement, FY2025
Net income increased 6.6% to $18.3B and diluted EPS rose 8.0% to $7.28, outpacing revenue growth and indicating meaningful margin improvement. This was partly supported by a 12.0% reduction in R&D expense to $15.8B, which declined from $17.9B in the prior year.
Source: Source: 10-K Income Statement, FY2025
Long-term debt surged 35.7% to $46.8B from $34.5B, while investing cash outflows nearly doubled to -$13.7B from -$7.7B, suggesting Merck made substantial acquisitions or capital investments during FY2025 to bolster its pipeline or expand capabilities.
Source: Source: 10-K Balance Sheet & Cash Flow Statement, FY2025
2 more insights available
Upgrade to unlockMerck's revenue is heavily dependent on a small number of blockbuster drugs, most notably Keytruda (pembrolizumab), which faces patent expiration in the late 2020s. Loss of exclusivity could result in rapid revenue erosion from generic and biosimilar competition, threatening a significant portion of the company's top line.
Source: Source: 10-K Risk Factors, FY2025
Unlock 4 more detailed risk analysis
Upgrade to unlockReported EPS of $2.09 versus the $2.03 analyst consensus — a +3.0% beat for FY2025.
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $65.01B | $64.17B | +1.31% |
Cost of Revenue | $16.38B | $15.19B | +7.83% |
Net Income | $18.25B | $17.12B | +6.64% |
EPS (Basic) | $7.30 | $6.76 | +7.99% |
EPS (Diluted) | $7.28 | $6.74 | +8.01% |
R&D Expense | $15.79B | $17.94B | -11.98% |
SG&A Expense | $10.73B | $10.82B | -0.77% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $136.87B | $117.11B | +16.87% |
Current Assets | $43.52B | $38.78B | +12.21% |
Current Liabilities | $28.33B | $28.42B | -0.33% |
Stockholders' Equity | $52.61B | $46.31B | +13.59% |
Cash & Equivalents | $14.56B | $13.24B | +9.99% |
Long-Term Debt | $46.75B | $34.46B | +35.66% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $16.47B | $21.47B | -23.27% |
Investing Cash Flow | $-13.74B | $-7.73B | -77.67% |
Financing Cash Flow | $-1.92B | $-7.03B | +72.67% |
Share Buybacks | $5.08B | $1.31B | +289.28% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 28.1% | — | — |
ROE | 34.7% | — | — |
ROA | 13.3% | — | — |
Current Ratio | $1.536 | — | — |
Other companies in Pharmaceuticals
Merck reported FY2025 revenue of $65.0B, up 1.3% year-over-year, with net income rising 6.6% to $18.3B and diluted EPS growing 8.0% to $7.28. However, operating cash flow declined 23.3% to $16.5B, and long-term debt surged 35.7% to $46.8B, reflecting significant acquisition or investment activity during the year.
Yes, Merck's diluted EPS grew 8.0% to $7.28 in FY2025, up from $6.74 in the prior year. The EPS growth outpaced revenue growth of 1.3%, supported by a 12.0% reduction in R&D expense and $5.1B in share repurchases that reduced the share count.
Merck's operating cash flow fell 23.3% to $16.5B in FY2025 from $21.5B in the prior year, a notable decline despite net income growth of 6.6%. The divergence likely reflects working capital changes, higher tax payments, or one-time cash items, and is worth monitoring in future quarters for signs of normalization.
Key risks for Merck include the impending patent expiration of Keytruda, its largest revenue driver, which could face biosimilar competition in the late 2020s. Additionally, the 35.7% surge in long-term debt to $46.8B increases financial leverage, and ongoing drug pricing pressures from the Inflation Reduction Act pose a threat to future revenue and margins.
Merck's financial health appears solid overall, with a net margin of 28.1%, ROE of 34.7%, and a current ratio of 1.54 indicating adequate liquidity. However, the sharp rise in long-term debt to $46.8B and the 23.3% decline in operating cash flow are areas investors should watch closely as potential vulnerabilities heading into the patent cliff period.